Literature DB >> 18681751

The use of antidepressants in bipolar disorder.

Virginio Salvi1, Andrea Fagiolini, Holly A Swartz, Giuseppe Maina, Ellen Frank.   

Abstract

BACKGROUND: Whether or not to use antidepressants in patients with bipolar disorder is a matter of debate. Antidepressant treatment of bipolar depression has been associated with manic switch and cycle acceleration. Furthermore, recent studies have argued against the efficacy of antidepressants in the treatment of bipolar depression. Nevertheless, many clinicians continue to employ antidepressants, especially in the management of severe depression that is unresponsive to mood stabilizers alone.
OBJECTIVE: Because of the unclear risk-to-benefit ratio of antidepressants in bipolar disorder, we have performed an updated review of the relevant literature. In this article we examine (1) all randomized controlled trials (RCTs) evaluating the use of antidepressants in the treatment of acute bipolar depression and assessing the risk of antidepressant-induced manic switch and (2) non-RCT trials that evaluate the impact of antidepressant discontinuation after acute antidepressant response. DATA SOURCES: A MEDLINE search of journals, covering the period from January 1966 to July 2007 and supplemented by bibliographic cross-referencing, was performed to identify the relevant studies. The keywords used were antidepressant, bipolar depression, bipolar disorder, switch, manic switch, antidepressant-induced mania, predictors, and antidepressant discontinuation. Criteria used to select studies included (1) English language and (2) studies published in peer-reviewed journals. DATA SYNTHESIS: Randomized, double-blind, placebo-controlled studies have demonstrated that antidepressants exert some efficacy in the treatment of bipolar depression in some populations of patients. Moreover, the risk of manic switch, although not totally countered, appears to be strongly reduced when antidepressants are given in combination with a mood stabilizer and when new-generation antide-pressants are preferred over old tricyclic antidepressants. Finally, some studies have proven that the continuous use of antidepressants after the remission of a major depressive episode helps to prevent further depressive relapses without causing a significant increase in manic relapses.
CONCLUSIONS: Clearly, there is a place for antidepressants in bipolar disorder; however, it is important to be cautious and evaluate their use on a case-by-case basis. Looking at specific depressive symptoms might help physicians in making the choice of whether to prescribe or not prescribe antidepressants.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18681751     DOI: 10.4088/jcp.v69n0816

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  17 in total

Review 1.  The catecholaminergic-cholinergic balance hypothesis of bipolar disorder revisited.

Authors:  Jordy van Enkhuizen; David S Janowsky; Berend Olivier; Arpi Minassian; William Perry; Jared W Young; Mark A Geyer
Journal:  Eur J Pharmacol       Date:  2014-08-05       Impact factor: 4.432

2.  The diagnosis and treatment of bipolar disorder: decision-making in primary care.

Authors:  Larry Culpepper
Journal:  Prim Care Companion CNS Disord       Date:  2014-06-19

Review 3.  Pharmacotherapy for the treatment of acute bipolar II depression: current evidence.

Authors:  Holly A Swartz; Michael E Thase
Journal:  J Clin Psychiatry       Date:  2010-08-10       Impact factor: 4.384

4.  Case report on the management of depression in schizoaffective disorder, bipolar type focusing on lithium levels and measurement-based care.

Authors:  Maju Mathew Koola; Jan A Fawcett; Deanna L Kelly
Journal:  J Nerv Ment Dis       Date:  2011-12       Impact factor: 2.254

Review 5.  The neurobiology of the switch process in bipolar disorder: a review.

Authors:  Giacomo Salvadore; Jorge A Quiroz; Rodrigo Machado-Vieira; Ioline D Henter; Husseini K Manji; Carlos A Zarate
Journal:  J Clin Psychiatry       Date:  2010-05-04       Impact factor: 4.384

Review 6.  Treating comorbid anxiety and depression: Psychosocial and pharmacological approaches.

Authors:  Jeremy D Coplan; Cindy J Aaronson; Venkatesh Panthangi; Younsuk Kim
Journal:  World J Psychiatry       Date:  2015-12-22

Review 7.  High-dose prazosin for the treatment of post-traumatic stress disorder.

Authors:  Maju Mathew Koola; Sajoy P Varghese; Jan A Fawcett
Journal:  Ther Adv Psychopharmacol       Date:  2014-02

8.  Higher pretreatment 5-HT1A receptor binding potential in bipolar disorder depression is associated with treatment remission: a naturalistic treatment pilot PET study.

Authors:  Martin J Lan; Natalie Hesselgrave; Adam Ciarleglio; R Todd Ogden; Gregory M Sullivan; J John Mann; Ramin V Parsey
Journal:  Synapse       Date:  2013-06-17       Impact factor: 2.562

9.  Subanesthetic dose ketamine does not induce an affective switch in three independent samples of treatment-resistant major depression.

Authors:  Mark J Niciu; David A Luckenbaugh; Dawn F Ionescu; Daniel C Mathews; Erica M Richards; Carlos A Zarate
Journal:  Biol Psychiatry       Date:  2013-05-28       Impact factor: 13.382

10.  Amphetamine increases activity but not exploration in humans and mice.

Authors:  Arpi Minassian; Jared W Young; Zackary A Cope; Brook L Henry; Mark A Geyer; William Perry
Journal:  Psychopharmacology (Berl)       Date:  2015-10-09       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.